Anlotinib
福可维(Anlotinib)
A Chinese-developed multi-kinase targeted pill.
At a glance
China price
Verified pricing is not currently available.
NRDL (national insurance)
In NRDL.
Regulatory status
NMPA approved (2018); NRDL (2018)
What this meansSupported by a credible secondary source but not yet independently confirmed against a primary source.
SourceNo independent source on file.
NotesApproval status from public regulatory reporting.
What it treats
Later-line NSCLC; soft-tissue sarcoma; SCLC.
Sources & verification
No independent source is currently on file. We have not independently verified this information.
Reader discussion
Public comments about Anlotinib. Discussion is not medical advice, and a comment is not an endorsement or a verified fact. Open the full forum.